Login

Consolidated Balance Sheets (Current Period Unaudited)

In millions of USD, except per-share amounts
Q1 FY2024
As of Mar 31, 2024
Q4 FY2023
As of Dec 31, 2023
Q3 FY2023
As of Sep 30, 2023
Q2 FY2023
As of Jun 30, 2023
Q1 FY2023
As of Mar 31, 2023
Q4 FY2022
As of Dec 31, 2022
Q3 FY2022
As of Sep 30, 2022
Q2 FY2022
As of Jun 30, 2022
Q1 FY2022
As of Mar 31, 2022
Q4 FY2021
As of Dec 31, 2021
Q3 FY2021
As of Sep 30, 2021
Q2 FY2021
As of Jun 30, 2021
Q1 FY2021
As of Mar 31, 2021
Q4 FY2020
As of Dec 31, 2020
Q3 FY2020
As of Sep 30, 2020
Q2 FY2020
As of Jun 30, 2020
Q1 FY2020
As of Mar 31, 2020
Q4 FY2019
As of Dec 31, 2019
Q3 FY2019
As of Sep 30, 2019
Q2 FY2019
As of Jun 30, 2019
Current assets:
Cash and cash equivalents
Accounts receivable, net of allowance for credit losses of $16 and $32
Finished goods
Raw materials
Packaging
Inventories
Other current assets
Current assets held for sale
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Intangible assets
Goodwill
Total goodwill
Long-term assets held for sale
Total assets
Current liabilities:
Accounts payable
Commodities payable
Accrued salary, wages and benefits
Accrued legal
Accrued expenses
Operating lease liabilities, current portion
Due under factoring agreement
Line of Credit With Bank
Factoring Agreement
Total due under factoring agreement
Due under insurance premium finance agreements
Finance lease liabilities, current portion
Current portion of long-term debt
Current liabilities held for sale
Total current liabilities
Operating lease liabilities, less current portion
Finance lease liabilities, less current portion
Long-term debt, net of unamortized discount
Derivative warrant liability
Long-term liabilities held for sale
Total liabilities
Shareholders' deficit:
Preferred stock, 20,000,000 shares authorized: Series G, convertible, 3,000 shares authorized, stated value $150, 150 shares, issued and outstanding
Series G Preferred Stock
Total preferred stock, 20,000,000 shares authorized: Series G, convertible, 3,000 shares authorized, stated value $150, 150 shares, issued and outstanding
Common stock, no par value, 15,000,000 shares authorized, 10,004,002 shares and 9,513,341 shares, issued and outstanding
Accumulated deficit
Total shareholders' deficit
Total liabilities and shareholders' deficit

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support